Author: Jiang, Ruirui ; Ding, Mengxia ; Yan, Fengbin ; Wang, Bingxin ; Kang, Xiangtao ; Han, Ruili ; Guo, Yujie ; Sun, Guirong ; Zhu, Zhaoyan ; Tian, Yadong ; Yu, Yange

In recent years, increasing interest has focused on natural components extracted from plants, among which plant polysaccharides as natural immunomodulators that can promote animal immunity. The present study was performed to investigate the effect of feed supplement Pseudostellaria Heterophylla Polysaccharide (PHP) on serum Immunoglobulins, T lymphocyte subpopulations, Cytokines and Lysozyme (LZM) activity in chicks. In addition, the influence of PHP on splenic gene expression was investigated by transcriptome sequencing. Four hundred 7-day-old Gushi cocks were randomly divided into four groups in a completely randomized design. The chicks were fed with a basal diet supplemented with 0 (CON-A), 100 (PHP-L), 200 (PHP-M) and 400 (PHP-H) mg/kg PHP. Blood and spleen samples were collected from 6 randomly selected chicks in each group at 14, 21, 28, and 35 days of age. The results showed that compared to the CON-A group, the PHP-M group exhibited significant increases in the levels of IgA, IgG, IgM, CD3, and LZM in the serum at 14, 21, 28, and 35 days (P < 0.05), and at 28 d, there was a significant quadratic relationship between the levels of dietary PHP and the levels of IgG, IgM, IFN-γ, IL-2, CD3, and LZM. Furthermore, a total of 470 differentially expressed genes (DEGs) were identified in spleen from PHP-M and CON-A at 28 d. These DEGs were significantly enriched in the Phagosome, Intestinal immune network for IgA production and Cytokine-cytokine receptor interaction pathways. The present investigation highlights the ameliorating effect of dietary PHP on immunological variables and spleen of chicks, the study suggests that PHP supplementation can enhance immunity and positively impact spleen mRNA expression in chicks.

21 Sep 2023·Bioengineering (Basel, Switzerland)

Effects of Cha-Cha Dance Training on Physical-Fitness-Related Indicators of Hearing-Impaired Students: A Randomized Controlled Trial.

Article

Author: Zhou, Zhenqian ; Qiu, Xuan ; Kim, Youngsuk ; Kim, Sukwon ; Li, Han

(1) Background: The physical fitness (PF) of hearing-impaired students has always been an international research hotspot since hearing-impaired students have difficulty in social interactions such as exercise or fitness programs. Sports interventions are proven to improve the fitness levels of hearing-impaired students; however, few studies evaluating the influence of Cha-cha (a type of Dance sport) training on the PF levels of hearing-impaired students have been conducted. (2) Purpose: This study aimed to intervene in hearing-impaired children through 12 weeks of Cha-cha dance training, evaluating its effects on their PF-related indicators, thus providing a scientific experimental basis for hearing-impaired children to participate in dance exercises effectively. (3) Methods: Thirty students with hearing impairment were randomly divided into two groups, and there was no difference in PF indicators between the two groups. The Cha-cha dance training group (CTG, n = 15) regularly participated in 90-min Cha-cha dance classes five times a week and the intervention lasted a total of 12 weeks, while the control group (CONG, n = 15) lived a normal life (including school physical education classes). Related indicators of PF were measured before and after the intervention, and a two-way repeated-measures analysis of variance was performed. (4) Results: After training, the standing long jump (CONG: 1.556 ± 0.256 vs. CTG: 1.784 ± 0.328, p = 0.0136, ES = 0.8081), sit-and-reach (CONG: 21.467 ± 4.539 vs. CTG: 25.416 ± 5.048, p = 0.0328, ES = 0.8528), sit-ups (CONG: 13.867 ± 4.912 vs. CTG: 27.867 ± 6.833, p < 0.0001, ES = 2.4677) and jump rope (CONG: 52.467 ± 29.691 vs. CTG: 68.600 ± 21.320, p = 0.0067, ES = 0.6547) scores showed significant differences. (5) Conclusions: After 12 weeks of Cha-cha dance training for hearing-impaired students, the PF level of hearing-impaired students in lower-body strength, flexibility, core strength, and cardiorespiratory endurance were effectively improved; however, there was no significant change in body shape, upper-body strength, vital capacity, and speed ability.

31 Aug 2023·Journal of materials science. Materials in medicine

Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles.

Article

Author: Moosazadeh Moghaddam, Mehrdad ; Mirnejad, Reza ; Bolouri, Shahin ; Golmohammadi, Reza ; Fasihi-Ramandi, Mahdi ; Heiat, Mohammad

Helicobacter pylori is the cause of most cases of stomach ulcers and also causes some digestive cancers. The emergence and spread of antibiotic-resistant strains of H. pylori is one of the most important challenges in the treatment of its infections. The present study aims to develop a concanavalin A (ConA) coated chitosan (CS) nanocarrier-based drug delivery for the targeted release of peptides to the site of H. pylori infection. Accordingly, chitosan was used as an encapsulating agent for CM11 peptide delivery by applying ionotropic gelation method. Con-A was used for coating CS nanoparticles to target H. pylori. The CS NPs and ConA-CS NPs were characterized by FTIR, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The MIC of CM11-loaded ConA-CS NPs against H. pylori SS1 strain was analyzed in vitro. In order to evaluate the treatment efficiency in vivo, a gastric infection model of H. pylori SS1 strain was established in mice and histopathological studies and IL-1β cytokine assay were performed. Based on the results, the size frequency for CS NPs and ConA-CS NPs was about 200 and 350 nm, respectively. The prepared CM11-loaded ConA-CS NPs exhibited antibacterial activity against H. pylori SS1 strain with a concentration of 32 µg/ml. The highest healing process was observed in synthesized CM11-loaded ConA-CS NPs treatments and a significant decrease in IL-1β was observed. Our findings highlight the potential of chitosan nanoparticles as a drug delivery vehicle in the treatment of gastric infection model of H. pylori SS1 strain.

News (Medical) associated with CGX-1007

28 Feb 2023

·www.prnewswire.com

The modular facility manufacturers market for pharmaceutical and biotechnology sectors is projected to grow at a CAGR of 9.9%, till 2035, claims Roots Analysis

Modular facilities can be an effective way for drug developers and manufacturers to reduce costs, minimize delays, and expedite time-to-market, by utilizing the available infrastructure while operating in accordance with the standard GMP guidelines LONDON, Feb. 28, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Modular Manufacturing / Modular Facilities Market: Focus on Pharmaceutical and Biotechnology Industry (3rd Edition), 2023-2035" report to its list of offerings. As traditional construction methods struggle with labor shortages, logistical obstacles and schedule delays, off-site or pre-engineered modular solutions are gaining traction, especially in the healthcare sector. Several pharmaceutical developers and contract service providers, globally, have already implemented modular facilities for flexible production capacities and smooth integration capabilities. To order this 300+ page report, which features 145+ figures and 175+ tables, please visit Key Market Insights 50+ players offer modular facilities and affiliated services to pharmaceutical / biotechnology firms It is worth mentioning that more than 45% of the modular facility providers, serving the healthcare sector, are based in Europe. Further, around 45% of the players are mid-sized companies (having 51-500 employees). Over 255 firms offer modular cleanroom services, including cleanroom components and utilities More than 50% of the players claim to have the required capabilities to offer hardwall cleanrooms, while nearly 35% of the firms offer softwall cleanrooms. In addition, different types of cleanroom components offered include doors (66%), pass-throughs (63%), HEPA filters (59%), air handling units (59%) and lighting and electrical functionalities (49%). Partnership activity in this field has grown at a CAGR of ~31%, between 2018 and 2022 Nearly 50% of the partnerships mentioned in the report were focused on modular facility construction. Further, about 20% of the total deals inked between stakeholders in this industry were service alliances, focused on enhancing the modular construction approaches. Over 70% of the 95+ modular projects were delivered in North America and Europe Of the total, 40% of the facilities built, so far, are large units (> 50,000 sq ft), followed by small facilities (5,001-20,000 sq ft). Further, more than 70% of the projects in this domain were focused on construction of manufacturing facilities, followed by aseptic filling facilities (20%). More than 185 facilities have been installed by various big pharma / biotech players It is worth noting that 50% of the facilities built are new facilities, followed by 27% instances of plant expansions. Additionally, 35 projects have received an investment of more than USD 300 million, of which, 28 were manufacturing facilities. The modular facility manufacturing market is likely to be driven by projects focused on cell and gene therapy production units, till 2035 Currently, North America captures the highest market share (45%), in terms of revenues from facility manufacturing projects, while the modular facilities market in Asia is likely to grow at a CAGR of 13.7%, till 2035. In the long term, hybrid-skid modular constructs are anticipated to capture the highest market share (33%), followed by skid-mounted modular solutions (30%). To request a sample copy / brochure of this report, please visit Frequently Asked Questions Who are the key service providers engaged in providing modular facility constructs to pharmaceutical and biotechnology industries? What are the key factors driving the adoption of modular facilities in the pharma / biotech industries? Which are the key regions where modular facilities are being installed by pharma / biotech firms? Which types of products are currently manufactured / processed in modular facilities? Which global regions are currently considered as hubs of modular construction service providers? What are the key strategies that can be implemented by emerging players / start-ups to enter this market? Which partnership models are commonly adopted by stakeholders in the modular facilities domain? How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity associated with the modular facility manufacturers market for pharmaceutical and biotechnology sectors has been analyzed across the following segments: Size of Facility Small Plants Mid-sized Plants Large Plants Very Large Plants Type of Industry Served Pharmaceutical Biotechnology Type of Modular Construct Hybrid Skid Modular Constructs Plug-and-Play Modular Constructs Skid-Mounted Modular Constructs Truckable Modular Constructs Others Modular Constructs Type of Construction Component Process Equipment Base Building Mechanical, Electrical and Plumbing System Process Commodities Other Construction Components Type of Facility Manufacturing Aseptic Filling Research and Development Others Scale of Operation Clinical Commercial Type of Product Cell and Gene Therapies Vaccines Biosimilars Monoclonal Antibodies Advanced Pharmaceuticals Sterile Products Viral Vectors Other Products Type of Expansion New Facilities Facility Expansions Planned Expansions Type of Modular Construction Relocatable Permanent Type of Material Steel Wood Concrete Key Geographical Regions North America Europe Asia Middle East and North Africa (MENA) Rest of the world The research includes brief profiles of key players offering modular facilities and related solutions (listed below); each profile features, an overview of the company, details related to its offerings, recent developments and an informed future outlook. Cytiva G-CON Manufacturing Germfree IPM Technologies KeyPlants ModuleCo Pharma NNE Pharmadule For additional details, please visit or email [email protected] You may also be interested in the following titles: Biologics Fill / Finish Services Market (3rd Edition), 2022-235 Cell and Gene Therapy CRO Market (3rd Edition). 2022-2035 Biopharmaceutical Contract Manufacturing Market, 2022-2035 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [email protected] Logo: SOURCE Roots Analysis

16 Feb 2023

·www.prnewswire.com

Worldwide Modular Manufacturing Facilities in Pharmaceutical and Biotechnology Indsutry to 2035: Increasing Preference and Demand for Personalized Therapies Drives Growth

DUBLIN, Feb. 15, 2023 /PRNewswire/ -- The "Modular Manufacturing Facilities Market in Pharmaceutical and Biotechnology: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and future opportunity, offering an informed opinion on the likely adoption of modular facilities in the pharmaceutical and biotechnology industries, over the next 12 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In the past few years, modular facilities or prefabricated buildings have emerged as a promising alternative to the conventionally built pharma / biotech manufacturing facilities. Modular manufacturing facility construction involves building of structures using prefabricated modular units, off-site, under controlled factory setting; these modular manufacturing units are later assembled on site. It is interesting to note that off-site construction can eliminate 60%-90% of the weather-related project concerns. Further, modular facilities can be built 40% faster as compared to a conventional construction, which could take up to three years. Therefore, considering the various advantages offered by this approach, several pharmaceutical players are now shifting their focus from conventional plants to modular manufacturing facilities. Specifically, modular facility providers are catering to the needs of various players engaged in the development of therapeutics, including cell and gene therapy, biosimilars and vaccines. To provide more context, modular biomanufacturing includes division of individual production processes, such as fermentation, purification and formulation, into separate modules that can be easily assembled and disassembled, allowing for flexibility and scalability. In addition, modular manufacturing allows the use of smaller-scale production units, which can be more flexible and responsive to dynamic market demands. Moreover, temporary modular buildings can be relocated after installation, based on needs of the end-user. However, mass production, complex decision-making, construction approvals and early financing can hinder the adoption of modular constructs. If healthcare stakeholders are able to overcome these challenges, modular construction can serve as a lucrative approach that provides greater flexibility and enables faster time-to-market for new products. This report features an extensive study of the current market landscape and future opportunity, offering an informed opinion on the likely adoption of modular facilities in the pharmaceutical and biotechnology industries, over the next 12 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Key Advantages Offered by Modular Facilities Modular manufacturing facilities have emerged as a promising alternative to conventional facilities owing to the multiple benefits that they offer. For instance, modular facilities can help in achieving 25%-30% reduction in the overall cost of construction, minimal plant site interruption, 50%-60% faster construction timelines, as well as ensure portability, safe working conditions and sustainability. In addition, better quality of products can be achieved by modular construction approaches owing to the fact that modules are built in a controlled factory setting. In addition, these modules are inspected more thoroughly and frequently before they are shipped to the construction site meeting desired quality standards. Moreover, modular construction allows more flexibility in terms of design, as a higher number of materials and finishes can be used, as compared to conventional facilities. Current Market Landscape of Modular Manufacturing Facilities The modular facilities market landscape features an extensive list of over 50 large, mid-sized, small and very small players. It is worth highlighting that more than 250 players are engaged in offering modular cleanrooms, along with various cleanroom accessories and customization options, in order to make them suitable for application in the life sciences industry. It is expected that modular facilities will become more streamlined and standardized in the future, serving as an efficient cost saving solution. Additionally, modular techniques allow building of smaller and specialized processing plants whenever rapid deployment of a therapy becomes critical in both developed and developing countries. Further, many, if not most, expansions and new facilities in the pharmaceutical and biotechnology industry are likely to be modular constructions in the near future. Key Drivers in the Modular Facilities Market Over the past few years, several factors have contributed to reform the facility construction paradigm within the pharmaceutical and biotechnology industries. The increasing preference and demand for personalized therapies and novel therapeutic interventions intended for the treatment of various ailments has compelled pharmaceutical companies to look beyond the traditional manufacturing and expansion practices. Lack of adequate manufacturing infrastructure, increased cost of construction and delay in project deliveries has collectively contributed to the emergence of off-site construction models. Overall Size of Modular Facilities Market Driven by the rising interest of stakeholders towards improvement of manufacturing and production efficiency, the anticipated lucrative opportunities and growth associated with adoption of modular manufacturing facilities, this market is expected to witness noteworthy growth in the foreseen future. Specifically, in terms of type of product, the market is anticipated to be driven by manufacturing units for cell and gene therapies, as well as vaccines and biosimilars. In addition, presently, close to 70% of the market share is captured by players based in North America and Europe. However, in the long run, markets in emerging regions, such as countries based in Asia, MENA and rest of the world are anticipated to grow at a faster pace. Example Players in the Modular Facilities Market Examples of players engaged in this domain (which have also been profiled in this report) include (in alphabetical order) Cytiva, G-CON Manufacturing, Germfree, IPM Technologies, KeyPlants, ModuleCo Pharma, NNE and Pharmadule. Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. MARKET LANDSCAPE: MODULAR FACILITY MANUFACTURERS 4.1. Chapter Overview 4.2. Modular Facility Manufacturers: Overall Market Landscape 5. MARKET LANDSCAPE: MODULAR CLEANROOM PROVIDERS 5.1. Chapter Overview 5.2. Modular Cleanroom Providers: Overall Landscape 5.2.1. Analysis by Year of Establishment 5.2.2. Analysis by Company Size 5.2.3. Analysis by Location of Headquarters 5.2.4. Analysis by Year of Establishment and Location of Headquarters 5.2.5. Analysis by Company Size and Location of Headquarters 5.2.6. Analysis by Type of Industry Served 5.2.7. Analysis by Location of Headquarters and Type of Industry Served 5.2.8. Analysis by Type of Modular Cleanroom Offered 5.2.9. Analysis by Type of Industry Served and Type of Modular Cleanroom Offered 5.2.10. Analysis by Type of Cleanroom Component Offered 5.2.11. Analysis by Type of Industry Served and Cleanroom Component Offered 5.2.12. Analysis by Type of Modular Cleanroom and Cleanroom Component Offered 5.2.13. Analysis by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom Offered 5.2.14. Analysis by Quality Certifications Obtained 6. MODULAR FACILITY MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS 6.1 Chapter Overview 6.2 Assumptions / Key Parameters 6.3 Methodology 6.4 Company Competitiveness Analysis: Modular Facility Manufacturers 6.4.1. Company Competitiveness Analysis: Benchmarking of Service Strength 6.4.2. Company Competitiveness Analysis: Benchmarking of Partnership activity 6.4.3. Company Competitiveness Analysis: Small Companies 6.4.4. Company Competitiveness Analysis: Mid-Sized Companies 6.4.5. Company Competitiveness Analysis: Large Companies 7. COMPANY PROFILES 7.1. Chapter Overview 7.2. Cytiva 7.2.1. Company Overview 7.2.2. Modular Facility-related Services 7.2.3. Modular Projects 7.2.4. Recent Developments and Future Outlook 7.3. G-CON Manufacturing 7.3.1. Company Overview 7.3.2. Modular Facility-related Services 7.3.3. Modular Projects 7.3.4. Recent Developments and Future Outlook 7.4. Germfree 7.4.1. Company Overview 7.4.2. Modular Facility-related Services 7.4.3. Modular Projects 7.4.4. Recent Developments and Future Outlook 7.5. IPM Technologies 7.5.1. Company Overview 7.5.2. Modular Facility-related Services 7.5.3. Modular Projects 7.5.4. Recent Developments and Future Outlook 7.6. KeyPlants 7.6.1. Company Overview 7.6.2. Modular Facility-related Services 7.6.3. Modular Projects 7.6.4. Recent Developments and Future Outlook 7.7. ModuleCo Pharma 7.7.1. Company Overview 7.7.2. Modular Facility-related Services 7.7.3. Modular Projects 7.7.4. Recent Developments and Future Outlook 7.8. NNE 7.8.1. Company Overview 7.8.2. Modular Facility-related Services 7.8.3. Modular Projects 7.8.4. Recent Developments and Future Outlook 7.9. Pharmadule 7.9.1. Company Overview 7.9.2. Modular Facility-related Services 7.9.3. Modular Projects 7.9.4. Recent Developments and Future Outlook 8. PARTNERSHIPS AND COLLABORATIONS 8.1. Chapter Overview 8.2. Partnership Models 8.3. Modular Facility Manufacturers: Partnerships and Collaborations 8.3.1. Analysis by Year of Partnership 8.3.2. Analysis by Type of Partnership 8.3.3. Analysis by Year of Partnership and Type of Partnership 8.3.4. Analysis by Type of Product 8.3.5. Analysis by Type of Partnership and Type of Product 8.3.6. Analysis by Type of Modular Facility 8.3.7. Analysis by Type of Product and Type of Modular Facility 8.3.8. Most Active Players: Analysis by Number of Partnerships 8.3.9. Analysis by Location of Partner's Headquarters 8.3.10. Analysis by Location of Modular Facility 8.3.11. Analysis by Type of Partnership and Location of Modular Facility 8.3.12. Analysis by Type of Product and Location of Modular Facility 8.3.13. Intercontinental and Intracontinental Partnerships 8.3.14. Analysis by Country 9. CASE STUDY ON MODULAR PROJECTS IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY 9.1. Chapter Overview 9.2. Modular Facility Projects Undertaken in the Pharmaceutical and Biotechnology Industry 9.3.1. Analysis by Type of Modular Facility 9.3.2. Analysis by Size of Modular Facility 9.3.3. Most Active Manufacturers: Analysis by Number of Projects Delivered 9.3.4. Most Active Clients: Analysis by Number of Projects Received 9.3.5. Analysis by Location of Modular Facility 9.3.6. Analysis by Type of Facility and Size of Modular Facility 9.3.7. Analysis by Client and Location of Facility 10. FACILITY CONSTRUCTION TRENDS IN THE PHARMACEUTICAL INDUSTRY 10.1. Chapter Overview 10.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry: Historical Data for Top 20 Players 10.2.1. Analysis by Number of Facilities Delivered 10.2.2. Analysis by Type of Facility 10.2.3. Analysis by Purpose of Facility 10.2.4. Analysis by Type of Facility and Purpose of Facility 10.2.5. Analysis by Type of Investment 10.2.6. Analysis by Purpose of Facility and Type of Investment 10.2.7. Analysis by Size of Facility 10.2.8. Analysis by Type of Facility and Size of Facility 10.2.9. Analysis by Purpose of Facility and Size of Facility 10.2.10. Analysis by Location of Headquarters 10.2.11. Analysis by Location of Facility 10.2.12. Analysis by Type of Facility and Location of Facility 11. COST-TIME OPTIMIZATION FRAMEWORK 11.1. Chapter Overview 11.2. Key Assumptions and Methodology 11.3. Factors Influencing Modular Construction 11.3.1. Intrinsic Factors 11.3.2. Extrinsic Factors 11.4. Cost Efficiency Analysis 11.5. Time-Benefit Analysis 11.6. Concluding Remarks 12. MARKET FORECAST 13. PREVALENT AND EMERGING INDUSTRY TRENDS 13.1. Chapter Overview 13.2. Adoption of Modular Facilities 13.3. Expansion of Existing Service Portfolio 13.4. Integration of Advanced Technologies 13.4.1. Single-use Technologies 13.4.2. Continuous Processing Technologies 13.4.3. Other Advanced Technologies 14. FUTURE GROWTH OPPORTUNITIES 14.1. Chapter Overview 14.2. Visibility Amongst Start-Ups 14.3. Popularity Amongst Contract Manufacturing Organizations 14.4. Expansion of Existing Facilities 14.5. Adoption for Production of Biosimilars 14.6. Additional Opportunities 14.7. Key Growth Drivers for Modular Construction 14.8. Market Attractiveness in Emerging regions 15. CONCLUSION 16. EXECUTIVE INSIGHTS 17. APPENDIX I: TABULATED DATA 18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with CGX-1007

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 1	US	Cognetix	-
Epilepsy	Phase 1	-	Precipio, Inc.	-
Epilepsy	Phase 1	-	Medtronic Plc	-
Nerve Degeneration	Phase 1	-	Medtronic Plc	-
Nerve Degeneration	Phase 1	-	Cognetix	-
Nerve Degeneration	Phase 1	-	Precipio, Inc.	-
Neurodegenerative Diseases	Phase 1	US	-	-
Pain	Preclinical	US	Cognetix	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis